XM does not provide services to residents of the United States of America.
G
G

Givaudan

Technical Summary

IndicatorValueTrend
IndicatorValueTrend
IndicatorValueTrend
IndicatorS3S2S1PR1R2R3

News

Symrise slips, analysts points to lack of beat, guidance hike

BUZZ-Symrise slips, analysts points to lack of beat, guidance hike ** Shares in Symrise SY1G.DE slip around 2% after it posted in-line H1 results and confirmed its guidance, with analysts noting that investors were likely expecting more ** "We believe the market was looking rather for a slight beat to the consensus," Konstantin Wiechert at Baader H
G
S
G

Symrise's half-year sales rise on fragrance business growth

UPDATE 2-Symrise's half-year sales rise on fragrance business growth H1 sales rise 6.3% year-on-year to 2.57 billion euros H1 EBITDA rises 11.5% to 529.8 million euros Sees 2024 organic growth at upper end of 5-7% guidance Adds CFO quote in paragraphs 5-6, share reaction in paragraph 8, analyst comments paragraph 9, division detail paragraph 11 By Antonis Pothitos Aug 1 (Reuters) - German flavour and fragrance maker Symrise SY1G.DE posted a 6.3% rise in its half-year sales on Thursday, in line w
G
K
L
S

Dsm-firmenich shares jump after core earnings forecast hike

UPDATE 2-Dsm-firmenich shares jump after core earnings forecast hike Adds CEO quote from analyst call in paragraphs 6-8, share move in paragraph 2 By Dimitri Rhodes and Anna Peverieri July 30 (Reuters) - Dutch chemicals maker dsm-firmenich DSFIR.AS raised its core earnings forecast for 2024 on Tuesday, banking on savings from the restructuring of its vitamin business and continued integration of DSM and Firmenich's legacy businesses.
G
S
N

Dsm-firmenich raises forecast on vitamin business

Dsm-firmenich raises forecast on vitamin business July 30 (Reuters) - Dutch chemicals maker dsm-firmenich DSFIR.AS raised its annual core earnings forecast on Tuesday, helped by the vitamin transformation programme and improving business conditions. The company now sees adjusted earnings before interest, tax, depreciation and amortisation (EBITDA) of around 2 billion euros ($2.16 billion) in 2024, up from the 1.9 billion euros previously forecast.
G
S

B&M, LVMH, Ocado

EUROPE RESEARCH ROUNDUP-B&M, LVMH, Ocado July 24 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including B&M, LVMH and Ocado on Wednesday. HIGHLIGHTS * B&M BMEB.L : JP Morgan cuts target price to 469p from 471p * LVMH LVMH.PA : Jefferies cuts target price to EUR 690 from EUR 710 * Ocado OCDO.L : HSBC raises target price to 305p from 285p * SAP SE SAPG.DE : Jefferies raises target price to EUR 225 from EUR 210 * Tharisa Plc THST.L : Peel Hu
3
A
C
D
E
E
E
E
E
E
G
G
K
L
O
S
T
A
A
B
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.